Restricted accessResearch articleFirst published online 2018-01
Effect of Tumor Necrosis Factor Alpha Dose and Exposure Time on Tumor Necrosis Factor-Induced Gene-6 Activation by Neonatal and Adult Mesenchymal Stromal Cells
Tumor necrosis factor alpha (TNF-α) induced protein 6 is a major anti-inflammatory mediator released by activated mesenchymal stromal cells (MSCs). Neonatal MSCs are considered more metabolically active than cells derived from adult tissues, and potentially less heterogeneous. We hypothesized that a TNF-α-activated neonatal MSC population [human umbilical cord perivascular cells (HUCPVCs)] would show an enhanced level of TSG-6 activation compared with adult bone marrow MSCs (BMMSCs). Thus, we stimulated HUCPVCs, and both human BMMSCs (hBMMSCs) and mouse BMMSCs (mBMMSCs) with 1, 10, 50, and 100 ng/mL of recombinant TNF-α over various exposure times. Supernatant, and total RNA, of the cells were collected for measurement of both TSG-6 RNA expression, and secreted TSG-6 protein. To compare gene levels, quantification was done by normalizing the expression levels of TSG-6 to the geometric mean of the three most stable reference genes, out of a cohort of 30 tested genes, using the Pfaffl method. We found that HUCPVCs exhibited both an enhanced and more rapid response to low dose (1 ng/mL) TNF-α exposure resulting in ∼11.5-fold increase in TSG-6 expression within the first 30 min. In contrast, hBMMSCs showed 2-fold increase by 1 h that increased to 9.5-fold with a higher (50 ng/mL) TNF-α exposure for the same time. mBMMSCs showed a two-fold increase after 24 h that was independent of TNF-α concentration. Thus, although TSG-6 expression level varied among donors, both hMSC populations exhibited enhanced TSG-6 upregulation, upon TNF-α stimulation, compared with mBMMSCs. In conclusion, HUCPVCs showed higher sensitivity, and a prompter response to TNF-α stimulation compared with hBMMSCs. Thus, neonatal MSCs may be a stronger candidate population than those derived from adult bone marrow to treat inflammatory diseases.
Get full access to this article
View all access options for this article.
References
1.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniFC, KrauseDS, DeansRJ, KeatingA, ProckopDJ and HorwitzEM. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
2.
RussellKC, LaceyMR, GilliamJK, TuckerHA, PhinneyDG and OconnorKC. (2011). Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency. Biotechnol Bioeng, 108:2716–2726.
3.
Ivanova-TodorovaE, BochevI, MourdjevaM, DimitrovR, BukarevD, KyurkchievS, TivchevP, AltunkovaI and KyurkchievDS. (2009). Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett, 126:37–42.
4.
LeeOK, KuoTK, ChenWM, LeeKD, HsiehSL and ChenTH. (2004). Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood, 103:1669–1675.
5.
ZhouC, YangB, TianY, JiaoH, ZhengW, WangJ and GuanF. (2011). Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes. Cell Immunol, 272:33–38.
6.
TomicS, DjokicJ, VasilijicS, VucevicD, TodorovicV, SupicG and ColicM. (2011). Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists. Stem Cells Dev, 20:695–708.
7.
WuTY, LiuY, WangB, SunYX, XuJ, Yuk-waiLW, XuLL, ZhangJF and LiG. (2016). The use of cocultured mesenchymal stem cells with tendon-derived stem cells as a better cell source for tendon repair. Tissue Eng Part A, 22:1229–1240.
8.
VishnubalajiR, Al-NbaheenM, KadalmaniB, AldahmashA and RameshT. (2012). Skin-derived multipotent stromal cells—an archrival for mesenchymal stem cells. Cell Tissue Res, 350:1–12.
9.
KinnairdT, StabileE, BurnettMS, ShouM, LeeCW, BarrS, FuchsS and EpsteinSE. (2004). Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation, 109:1543–1549.
10.
DaviesJE, WalkeJT, and KeatingA. (2017). Wharton's jelly: the rich, but enigmatic, source of MSCs. Stem Cell Trans Med, 6:1620–1630.
11.
BarciaRN, SantosJM, FilipeM, TeixeiraM, MartinsJP, AlmeidaJ, Agua-DoceA, AlmeidaSC, VarelaA, et al. (2015). What makes umbilical cord tissue-derived mesenchymal stromal cells superior immunomodulators when compared to bone marrow derived mesenchymal stromal cells?. Stem Cells Int, 2015:583984.
12.
PrasannaSJ, GopalakrishnanD, ShankarSR and VasandanAB. (2010). Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One, 5:e9016.
13.
LiX, BaiJ, JiX, LiR, XuanY and WangY. (2014). Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med, 34:695–704.
14.
BarlowS, BrookeG, ChatterjeeK, PriceG, PelekanosR, RossettiT, DoodyM, VenterD, PainS, GilshenanK and AtkinsonK. (2008). Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev, 17:1095–1107.
15.
HassR, KasperC, BohmS and JacobsR. (2011). Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 9:12.
16.
SarugaserR, LickorishD, BakshD, HosseiniMM and DaviesJE. (2005). Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells, 23:220–229.
17.
LuLL, LiuYJ, YangSG, ZhaoQJ, WangX, GongW, HanZB, XuZS, LuYX, et al. (2006). Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica, 91:1017–1026.
18.
CaplanAI. (2009). Why are MSCs therapeutic? New data: new insight. J Pathol, 217:318–324.
19.
BakshD, YaoR and TuanRS. (2007). Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells, 25:1384–1392.
20.
LiHZ, GhazanfariR, ZacharakiD, LimHC and SchedingS. (2016). Isolation and characterization of primary bone marrow mesenchymal stromal cells. Ann N Y Acad Sci, 1370:109–118.
21.
DayanV, YannarelliG, BilliaF, FilomenoP, WangXH, DaviesJE and KeatingA. (2011). Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res Cardiol, 106:1299–1310.
22.
EnnisJ, GotherstromC, Le BlancK and DaviesJE. (2008). In vitro immunologic properties of human umbilical cord perivascular cells. Cytotherapy, 10:174–181.
23.
HolleyRJ, TaiG, WilliamsonAJ, TaylorS, CainSA, RichardsonSM, MerryCL, WhettonAD, KieltyCM and CanfieldAE. (2015). Comparative quantification of the surfaceome of human multipotent mesenchymal progenitor cells. Stem Cell Reports, 4:473–488.
24.
CaplanAI and DennisJE. (2006). Mesenchymal stem cells as trophic mediators. J Cell Biochem, 98:1076–1084.
25.
LiuL, YuY, HouY, ChaiJ, DuanH, ChuW, ZhangH, HuQ and DuJ. (2014). Human umbilical cord mesenchymal stem cells transplantation promotes cutaneous wound healing of severe burned rats. PLoS One, 9:e88348.
26.
LiuL, SongH, DuanH, ChaiJ, YangJ, LiX, YuY, ZhangX, HuX, et al. (2016). TSG-6 secreted by human umbilical cord-MSCs attenuates severe burn-induced excessive inflammation via inhibiting activations of P38 and JNK signaling. Sci Rep, 6:30121.
27.
CaoH, YangJ, YuJ, PanQ, LiJ, ZhouP, LiY, PanX, LiJ, WangY and LiL. (2012). Therapeutic potential of transplanted placental mesenchymal stem cells in treating Chinese miniature pigs with acute liver failure. BMC Med, 10:56.
28.
RaicevicG, NajarM, StamatopoulosB, De BruynC, MeulemanN, BronD, ToungouzM and LagneauxL. (2011). The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol, 270:207–216.
29.
LeeRH, PulinAA, SeoMJ, KotaDJ, YlostaloJ, LarsonBL, Semprun-PrietoL, DelafontaineP and ProckopDJ. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5:54–63.
30.
ChoiH, LeeRH, BazhanovN, OhJY and ProckopDJ. (2011). Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood, 118:330–338.
31.
LeeRH, YuJM, FoskettAM, PeltierG, ReneauJC, BazhanovN, OhJY and ProckopDJ. (2014). TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc Natl Acad Sci U S A, 111:16766–16771.
32.
TsukaharaS, IkedaR, GotoS, YoshidaK, MitsumoriR, SakamotoY, TajimaA, YokoyamaT, TohS, FurukawaK and InoueI. (2006). Tumour necrosis factor alpha-stimulated gene-6 inhibits osteoblastic differentiation of human mesenchymal stem cells induced by osteogenic differentiation medium and BMP-2. Biochem J, 398:595–603.
33.
MahoneyDJ, MikeczK, AliT, MabilleauG, BenayahuD, PlaasA, MilnerCM, DayAJ and SabokbarA. (2008). TSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activation. J Biol Chem, 283:25952–25962.
34.
OhJY, RoddyGW, ChoiH, LeeRH, YlostaloJH, RosaRHJr. and ProckopDJ. (2010). Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci U S A, 107:16875–16880.
35.
DyerDP, SalangaCL, JohnsSC, ValdambriniE, FusterMM, MilnerCM, DayAJ and HandelTM. (2016). The anti-inflammatory protein TSG-6 regulates chemokine function by inhibiting chemokine/glycosaminoglycan interactions. J Biol Chem, 291:12627–12640.
36.
MindrescuC, DiasAA, OlszewskiRJ, KleinMJ, ReisLF and WisniewskiHG. (2002). Reduced susceptibility to collagen-induced arthritis in DBA/1J mice expressing the TSG-6 transgene. Arthritis Rheum, 46:2453–2464.
37.
QiY, JiangD, SindrilaruA, StegemannA, SchatzS, TreiberN, RojewskiM, SchrezenmeierH, Vander BekenS, et al. (2014). TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol, 134:526–537.
38.
BardosT, KamathRV, MikeczK and GlantTT. (2001). Anti-inflammatory and chondroprotective effect of TSG-6 (tumor necrosis factor-alpha-stimulated gene-6) in murine models of experimental arthritis. Am J Pathol, 159:1711–1721.
39.
MedicineT. (2017). MSC Distribution [online], Medicine.tamhsc.edu, https://medicine.tamhsc.edu/irm/msc-distribution.html (accessed August28, 2017).
BustinSA, BenesV, GarsonJA, HellemansJ, HuggettJ, KubistaM, MuellerR, NolanT, PfafflMW, et al. (2009). The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem, 55:611–622.
42.
KuiL, ChanGC and LeePP. (2017). TSG-6 downregulates IFN-alpha and TNF-alpha expression by suppressing IRF7 phosphorylation in human plasmacytoid dendritic cells. Mediators Inflam, 2017:7462945.
43.
UmS, KimHY, LeeJH, SongIS and SeoBM. (2017). TSG-6 secreted by mesenchymal stem cells suppresses immune reactions influenced by BMP-2 through p38 and MEK mitogen-activated protein kinase pathway. Cell Tissue Res, 368:551–561.
44.
Andrade JuniorDR, SantosSA, CastroI and AndradeDR. (2008). Correlation between serum tumor necrosis factor alpha levels and clinical severity of tuberculosis. Braz J Infect Dis, 12:226–233.
45.
SchutzeS, WiegmannK, MachleidtT and KronkeM. (1995). TNF-induced activation of NF-kappa B. Immunobiology, 193:193–203.
46.
ProckopDJ. (2016). Inflammation, fibrosis, and modulation of the process by mesenchymal stem/stromal cells. Matrix Biol, 51:7–13.
47.
de BeauxAC, GoldieAS, RossJA, CarterDC and FearonKC. (1996). Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg, 83:349–353.
48.
FerreiraRC, IanniBM, AbelLC, BuckP, MadyC, KalilJ and Cunha-NetoE. (2003). Increased plasma levels of tumor necrosis factor-alpha in asymptomatic/“indeterminate” and Chagas disease cardiomyopathy patients. Mem Inst Oswaldo Cruz, 98:407–411.
49.
BruunsgaardH, SkinhøjP, PedersenAN, SchrollM and PedersenBK. (2000). Ageing, tumour necrosis factor-alpha (TNF-α) and atherosclerosis. Clin Exp Immunol, 121:255–260.
50.
ZhaoSP and ZengLH. (1997). Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia. Int J Cardiol, 58:257–261.
51.
WarzochaK, SallesG, BienvenuJ, BarbierY, BastionY, DocheC, RieuxC and CoiffierB. (1997). Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas. Leukemia, 11 (Suppl 3):441–443.
52.
DanisVA, FranicGM, RathjenDA, LaurentRM and BrooksPM. (1992). Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann Rheum Dis, 51:946–950.
53.
DorgeSE, Roux-LombardP, DayerJM, KochKM, FreiU and LonnemannG. (1994). Plasma levels of tumor necrosis factor (TNF) and soluble TNF receptors in kidney transplant recipients. Transplantation, 58:1000–1008.
54.
AsumdaFZ and ChasePB. (2011). Age-related changes in rat bone-marrow mesenchymal stem cell plasticity. BMC Cell Biol, 12:44.
55.
KretlowJD, JinYQ, LiuW, ZhangWJ, HongTH, ZhouG, BaggettLS, MikosAG and CaoY. (2008). Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol, 9:60.
56.
BeaneOS, FonsecaVC, CooperLL, KorenG and DarlingEM. (2014). Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One, 9:e115963.
57.
LeijsMJ, van BuulGM, VerhaarJA, HoogduijnMJ, BosPK and van OschGJ. (2017). Pre-treatment of human mesenchymal stem cells with inflammatory factors or hypoxia does not influence migration to osteoarthritic cartilage and synovium. Am J Sports Med, 45:1151–1161.
58.
ZiaeiR, AyatollahiM, YaghobiR, SahraeianZ and ZarghamiN. (2014). Involvement of TNF-alpha in differential gene expression pattern of CXCR4 on human marrow-derived mesenchymal stem cells. Mol Biol Rep, 41:1059–1066.
59.
BaekSJ, KangSK and RaJC. (2011). In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med, 43:596–603.
60.
LeeMJ, KimJ, KimMY, BaeYS, RyuSH, LeeTG and KimJH. (2010). Proteomic analysis of tumor necrosis factor-alpha-induced secretome of human adipose tissue-derived mesenchymal stem cells. J Proteome Res, 9:1754–1762.
61.
LiuG-Y, LiuY, LuY, QinY-R, DiG-H, LeiY-H, LiuH-X, LiY-Q, WuC, HuX-W and DuanH-F. (2016). Short-term memory of danger signals or environmental stimuli in mesenchymal stem cells: implications for therapeutic potential. Cell Mol Immunol, 13:369–378.
ZahnG and GreischelA. (1989). Pharmacokinetics of tumor necrosis factor alpha after intravenous administration in rats. Dose dependence and influence of tumor necrosis factor beta. Arzneimittelforschung, 39:1180–1182.
64.
WangN, LiQ, ZhangL, LinH, HuJ, LiD, ShiS, CuiS, ZhouJ, JiJ, WanJ, CaiG and ChenX. (2012). Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6. PLoS One, 7:e43768.
65.
VandesompeleJ, De PreterK, PattynF, PoppeB, Van RoyN, De PaepeA and SpelemanF. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol, 3:RESEARCH0034.
66.
WangSS, HuSW, ZhangQH, XiaAX, JiangZX and ChenXM. (2015). Mesenchymal stem cells stabilize atherosclerotic vulnerable plaque by anti-inflammatory properties. PLoS One, 10:e0136026.
67.
ZhangR, LiuY, YanK, ChenL, ChenXR, LiP, ChenFF and JiangXD. (2013). Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflammation, 10:106.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
